Clinical trial / 2012
Resveratrol supplementation for 12 weeks did not improve metabolic function or insulin sensitivity in nonobese postmenopausal women with normal glucose tolerance.
A randomized, double-blind, placebo-controlled trial evaluated the metabolic effects of 12 weeks of resveratrol supplementation (75 mg/day) in nonobese, postmenopausal women with normal glucose tolerance. Resveratrol supplementation increased plasma resveratrol concentration but did not change body composition, resting metabolic rate, plasma lipids, or inflammatory markers. A hyperinsulinemic-euglycemic clamp procedure revealed no increase in liver, skeletal muscle, or adipose tissue insulin sensitivity, and resveratrol did not alter molecular targets including AMPK, SIRT1, NAMPT, and PPARGC1A in muscle or adipose tissue.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- Nonobese, postmenopausal women with normal glucose tolerance (sample size not stated)
- What was measured
- Body composition, resting metabolic rate, plasma lipids, inflammatory markers, insulin sensitivity, and molecular targets (AMPK, SIRT1, NAMPT, PPARGC1A)
THE PAPER
Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance.
Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S. Cell Metab, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.